Wuxi XDC Cayman Inc. (2268)

Overview

WuXi XDC Cayman Inc. stands as a prominent investment holding entity, delving into the intricate world of contract research, development, and manufacturing with a global operational footprint across China, North America, Europe, and beyond. Initiated in 2013 and placing its headquarters in Wuxi, China, the company is renowned for its profound expertise in the biopharmaceutical sector, particularly in the realm of antibody drug conjugates and bioconjugates. Operating under the umbrella of WuXi Biologics (Cayman) Inc., it plays a pivotal role as a subsidiary, contributing significantly to healthcare advancements by providing comprehensive solutions in drug discovery, research, development, and manufacturing.

Products and Services

The portfolio of WuXi XDC Cayman Inc. is distinguished by its specialized focus on the following areas:

• Antibody Drug Conjugates (ADCs)

  This is a cutting-edge class of therapeutics that uniquely combines the specificity of antibodies with the potency of cytotoxic drugs, aimed at targeting and killing cancer cells while sparing healthy tissue. WuXi XDC's involvement in ADCs signifies its commitment to pioneering cancer treatments through innovation.

• Monoclonal Antibody Intermediates

  These refer to partially processed substances that are critical components in the production of monoclonal antibodies, which are used in a variety of therapeutic treatments. The company's expertise in monoclonal antibody intermediates underscores its capability in supporting the development and manufacture of next-generation biopharmaceuticals.

• Payload-Linkers Associated with Bioconjugates

  This advanced area focuses on the technology and the components needed to create bioconjugates, including both the payload (drug) itself and the linker that attaches it to a carrier, such as an antibody. WuXi XDC Cayman Inc.'s work in this domain is essential for the creation of more effective and safer therapeutics.

• Bioconjugates

  A broad category that encompasses various types of molecules conjugated to biological compounds. These are used for targeting specific cells or pathways and are a crucial component in the development of targeted therapies. By engaging in the research, development, and manufacturing of bioconjugates, WuXi XDC plays a vital role in advancing precision medicine.